Tonix Pharmaceuticals Stock Forecast, Price & News

-0.03 (-4.85 %)
(As of 09/20/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume13.62 million shs
Average Volume21.15 million shs
Market Capitalization$210.58 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive TNXP News and Ratings via Email

Sign-up to receive the latest news and ratings for Tonix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Tonix Pharmaceuticals logo

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.78 out of 5 stars

Medical Sector

789th out of 1,352 stocks

Pharmaceutical Preparations Industry

387th out of 665 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Tonix Pharmaceuticals (NASDAQ:TNXP) Frequently Asked Questions

Is Tonix Pharmaceuticals a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tonix Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Tonix Pharmaceuticals stock.
View analyst ratings for Tonix Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Tonix Pharmaceuticals?

Wall Street analysts have given Tonix Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Tonix Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Tonix Pharmaceuticals?

Tonix Pharmaceuticals saw a drop in short interest in August. As of August 13th, there was short interest totaling 13,920,000 shares, a drop of 12.8% from the July 29th total of 15,960,000 shares. Based on an average daily trading volume, of 11,400,000 shares, the short-interest ratio is presently 1.2 days.
View Tonix Pharmaceuticals' Short Interest

When is Tonix Pharmaceuticals' next earnings date?

Tonix Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Tonix Pharmaceuticals

How were Tonix Pharmaceuticals' earnings last quarter?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) posted its quarterly earnings data on Sunday, August, 8th. The company reported ($0.07) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.07).
View Tonix Pharmaceuticals' earnings history

How has Tonix Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Tonix Pharmaceuticals' stock was trading at $0.8311 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TNXP shares have decreased by 29.1% and is now trading at $0.5890.
View which stocks have been most impacted by COVID-19

When did Tonix Pharmaceuticals' stock split? How did Tonix Pharmaceuticals' stock split work?

Shares of Tonix Pharmaceuticals reverse split on the morning of Wednesday, November 28th 2018. The 1-10 reverse split was announced on Tuesday, November 27th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, November 27th 2018. An investor that had 100 shares of Tonix Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for TNXP?

1 brokerages have issued twelve-month target prices for Tonix Pharmaceuticals' shares. Their forecasts range from $2.00 to $2.00. On average, they expect Tonix Pharmaceuticals' stock price to reach $2.00 in the next year. This suggests a possible upside of 239.6% from the stock's current price.
View analysts' price targets for Tonix Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Tonix Pharmaceuticals' key executives?

Tonix Pharmaceuticals' management team includes the following people:
  • Seth Lederman, Chairman, President & Chief Executive Officer
  • Jessica Edgar Morris, Chief Operating Officer
  • Bradley Saenger, Treasurer & Chief Financial Officer
  • Gregory M. Sullivan, Secretary & Chief Medical Officer

Who are some of Tonix Pharmaceuticals' key competitors?

What other stocks do shareholders of Tonix Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tonix Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Vaxart (VXRT), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Rite Aid (RAD), Heat Biologics (HTBX), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), VBI Vaccines (VBIV) and ADMA Biologics (ADMA).

What is Tonix Pharmaceuticals' stock symbol?

Tonix Pharmaceuticals trades on the NASDAQ under the ticker symbol "TNXP."

Who are Tonix Pharmaceuticals' major shareholders?

Tonix Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.05%), Vanguard Group Inc. (4.41%), Renaissance Technologies LLC (2.01%), Geode Capital Management LLC (1.54%), State Street Corp (1.43%) and Northern Trust Corp (0.87%). Company insiders that own Tonix Pharmaceuticals stock include Daniel Wintner Goodman, Gregory M Sullivan, James Treco, Margaret Smith Bell and Seth Lederman.
View institutional ownership trends for Tonix Pharmaceuticals

Which institutional investors are selling Tonix Pharmaceuticals stock?

TNXP stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Goldman Sachs Group Inc., Millennium Management LLC, Bridgeway Capital Management LLC, and First Trust Advisors LP.
View insider buying and selling activity for Tonix Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Tonix Pharmaceuticals stock?

TNXP stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Geode Capital Management LLC, Northern Trust Corp, Nuveen Asset Management LLC, Vanguard Group Inc., Bank of New York Mellon Corp, and Charles Schwab Investment Management Inc.. Company insiders that have bought Tonix Pharmaceuticals stock in the last two years include Daniel Wintner Goodman, Gregory M Sullivan, James Treco, Margaret Smith Bell, and Seth Lederman.
View insider buying and selling activity for Tonix Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Tonix Pharmaceuticals?

Shares of TNXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tonix Pharmaceuticals' stock price today?

One share of TNXP stock can currently be purchased for approximately $0.59.

How much money does Tonix Pharmaceuticals make?

Tonix Pharmaceuticals has a market capitalization of $210.58 million. The company earns $-50,460,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis.

How many employees does Tonix Pharmaceuticals have?

Tonix Pharmaceuticals employs 26 workers across the globe.

What is Tonix Pharmaceuticals' official website?

The official website for Tonix Pharmaceuticals is

Where are Tonix Pharmaceuticals' headquarters?

Tonix Pharmaceuticals is headquartered at 509 MADISON AVENUE SUITE 1608, NEW YORK NY, 10022.

How can I contact Tonix Pharmaceuticals?

Tonix Pharmaceuticals' mailing address is 509 MADISON AVENUE SUITE 1608, NEW YORK NY, 10022. The company can be reached via phone at (212) 980-9155 or via email at [email protected].

This page was last updated on 9/21/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.